Cullinan Therapeutics (CGEM) Profit After Tax (2021 - 2023)
Historic Profit After Tax for Cullinan Therapeutics (CGEM) over the last 3 years, with Q4 2023 value amounting to -$25.6 million.
- Cullinan Therapeutics' Profit After Tax rose 455.16% to -$25.6 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$155.1 million, marking a year-over-year decrease of 24057.41%. This contributed to the annual value of -$167.6 million for FY2024, which is 804.25% down from last year.
- Per Cullinan Therapeutics' latest filing, its Profit After Tax stood at -$25.6 million for Q4 2023, which was up 455.16% from -$39.2 million recorded in Q3 2023.
- In the past 5 years, Cullinan Therapeutics' Profit After Tax registered a high of $174.9 million during Q2 2022, and its lowest value of -$58.1 million during Q1 2023.
- Moreover, its 3-year median value for Profit After Tax was -$25.2 million (2022), whereas its average is -$9.4 million.
- Over the last 5 years, Cullinan Therapeutics' Profit After Tax had its largest YoY gain of 116392.12% in 2022, and its largest YoY loss of 100852.71% in 2022.
- Cullinan Therapeutics' Profit After Tax (Quarter) stood at -$34.2 million in 2021, then increased by 21.7% to -$26.8 million in 2022, then grew by 4.55% to -$25.6 million in 2023.
- Its last three reported values are -$25.6 million in Q4 2023, -$39.2 million for Q3 2023, and -$32.2 million during Q2 2023.